Quick Read <\/p>\n
Dislocation between share price and product progress is exactly the kind of setup retail investors should scan for.<\/p>\n
Here are seven healthcare AI stocks trading under $50 where the bull case is grounded, not hype.<\/p>\n
The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbCellera Biologics wasn’t one of them. Get them here FREE<\/a>.<\/p>\n Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful multi-year execution path can plausibly deliver triple-digit returns. The $50 ceiling is the filter; the AI flywheel is the thesis.<\/p>\n With that in mind, here are seven healthcare AI stocks trading under $50 where the bull case is grounded in product, partnership, or platform data, not hype.<\/p>\n Tempus AI <\/p>\n Tempus AI (NASDAQ: TEM<\/a>) pairs genomic diagnostics with a massive healthcare data library that pharma partners license for AI-driven drug discovery. At around $43.93, shares are down 25.6% year to date and are well below the $67.20 analyst target price, with 10 Buy or Strong Buy ratings against one Sell.<\/p>\n The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbCellera Biologics wasn’t one of them. Get them here FREE<\/a>.<\/p>\n Q4 2025 revenue grew 83% year over year to $367.21 million, adjusted EBITDA flipped positive at $12.89 million, and 2026 guidance calls for $1.59 billion in revenue and roughly $65 million in adjusted EBITDA. CEO Eric Lefkofsky said “network effects from our investments in AI continue to compound,” backed by deepening partnerships with Gilead, Merck, and Daiichi Sankyo. The risk is that an accumulated deficit of $2.4 billion, heavy stock-based comp, and the $460 million in convertible notes priced in May 2026 add dilution and execution risk. Still, the data flywheel keeps spinning.<\/p>\n Hims & Hers Health <\/p>\n Hims & Hers Health (NYSE: HIMS<\/a>) runs a direct-to-consumer telehealth platform that uses AI to personalize care across weight loss, dermatology, mental health, and sexual wellness. At about $25.05 a share, the stock is down 57.2% over one year, with a forward P\/E near 48x.<\/p>\n FY2026 guidance was raised to $2.80 billion to $3.00 billion in revenue and $275 million to $350 million in adjusted EBITDA, and management is targeting $6.5 billion in revenue and $1.3 billion adjusted EBITDA by 2030. International revenue surged 969% to $78.19 million, and a $250 million buyback was authorized. CEO Andrew Dudum called 2026 “a defining year.” The bull case is based on subscriber growth, the Novo Nordisk branded GLP-1 partnership, and international scaling. Notably, Q1 2026 EPS missed consensus estimates by 396.74%, U.S. revenue declined, and ongoing FDA and securities lawsuits around compounded GLP-1s remain unresolved.<\/p>\n Story Continues <\/p>\n Doximity <\/p>\n Doximity (NYSE: DOCS<\/a>) operates the dominant professional network for U.S. physicians, now layered with Doximity GPT and clinical AI workflow tools. Trading at around $18.97, the stock is down 57.2% year to date, with a PEG ratio of 0.715 and a forward P\/E near 16x.<\/p>\n The platform now reaches 800,000+ active prescribers, with nearly half using clinical AI and prompts per user nearly doubling between January and April 2026. FY2026 generated $644.86 million in revenue, $196.05 million in net income, and $317.50 million in free cash flow, and the company repurchased $431.7 million of stock. The triple-digit upside thesis depends on AI engagement converting into pharma ad pricing power. The risk here is that FY2027 revenue guidance of $664 million to $676 million implies meaningful growth deceleration, and stock-based comp doubled. The cash generation cushions the multi-year story.<\/p>\n Nurix Therapeutics <\/p>\n Nurix Therapeutics (NASDAQ: NRIX<\/a>) applies an AI and computational platform to targeted protein degradation, a next-generation drug modality. At about $15.86, shares are well below the $30.18 analyst target, with 17 Buy or Strong Buy ratings and zero Holds or Sells.<\/p>\n Lead asset bexobrutideg, a BTK degrader, is enrolling the Phase 2 DAYBreak CLL-201 study, with Phase 3 DAYBreak CLL-306 set to start mid-2026 and an IND submission planned in autoimmune indications. CEO Arthur Sands has positioned bex as a “potential best-in-class” CLL therapy. Active collaborations with Gilead, Sanofi, and Pfizer carry 50\/50 U.S. profit-share opt-ins, and $540.73 million in cash may fund the runway through 2027 readouts. However, Q1 revenue collapsed 66.1% year over year as the Sanofi initial research term expired, and clinical trials can fail at any stage.<\/p>\n Schr\u00f6dinger <\/p>\n Schrodinger (NASDAQ: SDGR<\/a>) combines physics-based simulation with AI in a drug discovery platform used by most major biopharma R&D groups. At around $11.95, the stock is down 33.2% year to date, with analysts targeting $20.88.<\/p>\n FY2026 guidance calls for ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million, with the Bunsen agentic AI co-scientist launching in summer 2026. Lilly’s pending acquisition of co-founded Ajax Therapeutics for up to $2.3 billion validates the ecosystem; Schrodinger holds a 5.8% stake. CEO Ramy Farid said, “the biopharmaceutical funding environment is improving,” which matters since software revenue is mid-transition. Yet operating cash flow swung to negative $14.83 million from positive $144 million year over year, and cash burn is meaningful. If Bunsen lands, the multi-year setup is compelling.<\/p>\n Phreesia <\/p>\n Phreesia (NYSE: PHR<\/a>) sells AI-enabled patient intake and provider workflow software to thousands of healthcare practices. At about $8.77, the stock is down 65.9% over one year, with an analyst target of $15.39 and a forward P\/E near 18x.<\/p>\n FY2026 delivered Phreesia’s first-ever positive GAAP net income year, with adjusted EBITDA above $100 million and free cash flow over $50 million. Q4 free cash flow set a record at $28.5 million, up 210%. CEO Chaim Indig said the “underlying platform is stronger than it has ever been.” The bull case is based on AI-driven margin expansion plus a depressed share price. Risk: FY2027 revenue guidance was cut to $510 million to $520 million on pharma manufacturer pullback in vaccines and GLP-1 categories, sending shares down roughly 25%. Profitability is durable; growth visibility is not.<\/p>\n AbCellera Biologics <\/p>\n